Rucaparib + Sacituzumab Govitecan: Initial Data From the Phase 1b/2 SEASTAR Study (NCT03992131)

Timothy A. Yap,1 Erika Hamilton,2 Todd Bauer,2 Ecaterina E. Dumbrava,1 Rinath Jeselsohn,3 Aaron Enke,4 Sabrina Hurley,4 Kevin Lin,4 Kenton Wride,4 Heidi Giordano,4 Geoffrey Shapiro3

1The University of Texas MD Anderson Cancer Center, Houston, USA; 2Sarah Cannon Research Institute at Tennessee Oncology, Nashville, USA; 3Dana-Farber Cancer Institute, Boston, USA; 4Clovis Oncology, Inc., Boulder, USA

ESMO Congress | 19–21 September 2020 | Virtual Meeting
Poster number: 547P

Supplementary Material
Dose-Limiting Toxicity Criteria

A dose-limiting toxicity (DLT) was defined as any of the following occurring within the first 21 days of initiating combination treatment (cycle 1) that was assessed by the investigator as possibly related to rucaparib and/or sacituzumab govitecan:

- Grade ≥3 febrile neutropenia (ie, fever >38.3°C with absolute neutrophil count <1.0 × 10^9/L) of any duration
- Grade 3 or 4 neutropenia lasting >7 days despite granulocyte colony-stimulating factor administration
- Grade 3 thrombocytopenia (platelets <50 × 10^9/L) with significant bleeding or grade 4 thrombocytopenia (platelets <25 × 10^9/L) ≥5 days duration
- Grade 4 anaemia (ie, life-threatening consequences; urgent intervention indicated) or any anaemia (regardless of grade or severity) requiring a blood transfusion
- Any nonhaematological adverse event grade ≥3, with the exception of:
  - Nausea, vomiting, and diarrhoea if well controlled by systemic medication and with duration ≤48 hr
  - Fatigue
  - Grade 3 alanine aminotransferase or aspartate aminotransferase (ALT/AST) increase not accompanied by a concomitant increase in total bilirubin above the upper limit of normal; any grade 4 ALT/AST increase was considered a DLT
- Any grade ≥3 infusion-related reaction that failed to resolve within 4 hours despite optimal medical management
## Patient Genomic Testing

<table>
<thead>
<tr>
<th>Patient</th>
<th>Local genomics tests performed</th>
<th>Deleterious HRR gene mutation identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>• MDACC Molecular Diagnostics Laboratory – Solid Tumor Genomic Assay</td>
<td>None detected</td>
</tr>
<tr>
<td>2</td>
<td>• Foundation Medicine – FoundationOne CDx</td>
<td>$BRCA1\ N1355fs*10$</td>
</tr>
<tr>
<td>3</td>
<td>• Guardant Health – Guardant360</td>
<td>$BRCA2\ E2846fs$</td>
</tr>
</tbody>
</table>
| 4       | • Invitae – Breast and Gyn Cancers Guidelines-Based Panel  
• Myriad Genetics – myChoice CDx  
• MDACC Molecular Diagnostics Laboratory – Solid Tumor Genomic Assay | None detected |
| 5       | • BWH Molecular Diagnostics Lab – OncoPanel | None detected |
| 6       | • No genetic testing done, no report available | Not tested |

BWH, Brigham and Women's Hospital; HRR, homologous recombination repair; MDACC, MD Anderson Cancer Center.
Supplementary Figure. Representative Images From Patient 5 With Metastatic TNBC and a Confirmed Partial Response
Supplementary Figure. Representative Images From Patient 5 With Metastatic TNBC and a Confirmed Partial Response (continued)

Baseline

Left pleural-based lesion

Mediastinal/Hilar/Prevascular lymphadenopathy*

Retrocrural lymph node*

Day 86

*Nontarget lesion, size not measured
Supplementary Figure. Representative Images From Patient 5 With Metastatic TNBC and a Confirmed Partial Response (continued)

Baseline

Left iliac lymph node*

Left inguinal lymph node*

Breast nodularity*

Day 86

*Nontarget lesion, size not measured